Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer

Prostate Cancer Clinical Trial

Official title: Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine the pharmacokinetics, dosimetry, tolerance, tumor detection rate of 68Ga-PSMA-33 in patient with Prostate Cancer (PCa).

Clinical Trial Description

This study is design to prospectively investigate the safety and efficacy of 68Ga-PSMA-33 in the early diagnosis of Prostate Cancer (PCa). The specific objectives are the determination of pharmacokinetics, dosimetry, tolerance and tumor detection rate of 68Ga-PSMA-33 in patient with PCa. While PSMA is expressed at low levels in normal prostate epithelium, it is overexpressed (up to 1000 times higher) in 90-95% of prostate cancers, make PSMA an attractive target for the diagnosis and treatment of PCa. 68Ga-PSMA-33 as a new PSMA targeted probe was prepared and showed good uptake on PCa cell line and animal studies. The study intends to recruit 8 PCa volunteers to participate in the experiment. All patients were intravenously injected with 68Ga-PSMA-33 and underwent PET/CT at 0.5, 1, 2 and 4 h, respectively. For comparison, 3 patients were additionally received 68Ga-PSMA-617 PET/CT imaging. The images were interpreted by two experienced physician and the SUVmax or SUVmean of physiological organs and tumor lesions were collected. ;

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT06054789
• Study type: Interventional
• Source: Nanjing First Hospital, Nanjing Medical University
• Contact: Feng Wang
• Phone: 02552271276
• Email: fengwangcn@hotmail.com
• Status: Recruiting
• Phase: N/A
• Start date: October 1, 2022
• Completion date: October 1, 2024